Latest News and Press Releases

Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone in patients with HGSOC

Artios receives FDA Fast Track designation for DNA polymerase theta (Polθ) inhibitor ART6043 for treatment of gBRCA-mutated HER2-negative breast cancer

Artios appoints Roy Ware (CMTO), Caryn Barnett (VP Clinical Operations) & Pablo Lee (VP Medical Affairs) to strengthen late-stage development capabilities

Artios Pharma to present at the 2026 J.P. Morgan Healthcare Conference, highlighting its ATR and Polθ inhibitor programs targeting DDR in cancer.

Funding advances Phase 2 expansion cohorts in pancreatic and colorectal cancer in ATM-negative patients for Artios’ potential first-in-class ATR Inhibitor, alnodesertib  Following encouraging ESMO...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage...

U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September...

Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high...

ART0380 in combination with low-dose irinotecan demonstrated a 50% confirmed overall response rate (cORR) in patients with Ataxia-Telangiectasia Mutated (ATM)-negative1 solid tumors at the...